First-in-class drug approvals

China approved 48 first-in-class innovative drugs in 2024, covering nearly 20 therapeutic areas, including oncology, neurological disorders, endocrine diseases and anti-infective medicines, according to a report released by the National Medical Products Administration on Tuesday.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V

Copy

MLA

National Medical Products Administration. "China approves 48 innovative drugs in 2024." 2024, https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V.

Copy

Chicago

National Medical Products Administration. "China approves 48 innovative drugs in 2024." 2024. https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V.

Copy

BibTeX

@misc{nmpa2024firstvvd25v, author = {{National Medical Products Administration}}, title = {China approves 48 innovative drugs in 2024}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V}, note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\_1079532.htm. Accessed September 17, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V.